Abstract Number: L10 • 2018 ACR/ARHP Annual Meeting
Clinical Efficacy of Leflunomide/Hydroxychloroquine Combination Therapy in Patients with Primary Sjogren’s Syndrome: Results of a Placebo-Controlled Double-Blind Randomized Clinical Trial
Background/Purpose: Primary Sjogren’s syndrome (pSS) is a systemic, progressive autoimmune disease characterized by secretory gland dysfunction which lacks effective therapy. Clinical trials in patients with…Abstract Number: L06 • 2018 ACR/ARHP Annual Meeting
Safety and Efficacy of Filgotinib in a Phase 3 Trial of Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic Dmards
Background/Purpose: Filgotinib (FIL), an oral, selective, Janus Kinase 1 (JAK1) inhibitor was effective in phase 2 studies of active RA in patients (pts) with insufficient…Abstract Number: 305 • 2018 ACR/ARHP Annual Meeting
Introduction and Value of a Shortened Psamris-7 in Psa-Patients before and after Treatment Escalation to Bdmard Using High Resolution MRI
Background/Purpose: The aim of the study was to evaluate a simplified version of the OMERACT Psoriasis Arthritis Magnetic Resonance Imaging Score (PsAMRIS) to seven regions…Abstract Number: 697 • 2018 ACR/ARHP Annual Meeting
Clinical Results of Patients with Peripheral Psoriatic Arthritis Not Receiving Biological Therapy in a Multidisciplinary Unit
Background/Purpose: We consider multidisciplinary management necessary, especially in a subgroup of patients with Psoriatic Arthritis (PsA) for complexity, cutaneous and / or joint involvement. Despite…Abstract Number: 1542 • 2018 ACR/ARHP Annual Meeting
Real-World Data from a Post-Approval Safety Surveillance Study of Tofacitinib Vs Biologic Dmards and Conventional Synthetic Dmards: Five-Year Results from a US-Based Rheumatoid Arthritis Registry
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. A prospective observational 5-year study, embedded within the US Corrona RA registry,…Abstract Number: 2468 • 2018 ACR/ARHP Annual Meeting
Window or No Window? Earlier Is Better When Treating Rheumatoid Arthritis
Background/Purpose: Previous reports on a window of opportunity (WOO) in rheumatoid arthritis (RA) may be related to the use of slow acting csDMARDs. We investigated…Abstract Number: 496 • 2018 ACR/ARHP Annual Meeting
Heart Failure Risk Among Patients with Rheumatoid Arthritis: Association with Anti-Rheumatic Drugs
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased risk of coronary artery disease (CAD), but the association with heart failure (HF) is less characterized. We…Abstract Number: 887 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of the Novel Oral Janus Kinase (JAK) Inhibitor, Peficitinib (ASP015K), in a Phase 3, Double-Blind, Placebo-Controlled, Randomized Study of Patients with RA Who Had an Inadequate Response to Dmards
Background/Purpose: Peficitinib (ASP015K), a novel oral JAK inhibitor, demonstrated efficacy as once-daily monotherapy in patients with moderate to severe RA in a phase 2b study…Abstract Number: 1659 • 2018 ACR/ARHP Annual Meeting
Sustained Improvements in Physical Function, Quality of Life, and Work Productivity after Ixekizumab Therapy in Patients with Active Psoriatic Arthritis: 3-Year Results
Background/Purpose: Ixekizumab (IXE), a high-affinity mAb that selectively targets IL-17A, has shown improvements compared to placebo not only in disease activity but also in various…Abstract Number: 2500 • 2018 ACR/ARHP Annual Meeting
Association between Anti-Citrullinated Protein Antibody Status, Erosive Disease and Healthcare Resource Utilization in Patients with RA
Background/Purpose: Anti-citrullinated protein antibody (ACPA) is a highly specific biomarker for RA1 and ACPA-seropositive patients have a tendency toward severe erosive disease and more rapid…Abstract Number: 543 • 2018 ACR/ARHP Annual Meeting
Disease Severity Among Bio-Naive RA Patients on Csdmards
Background/Purpose: Conventional synthetic disease-modifying anti-rheumatic drugs (csDMARD) are recommended as the first-line treatment for patients with rheumatoid arthritis (RA). Guidelines recommend escalation of treatment to…Abstract Number: 940 • 2018 ACR/ARHP Annual Meeting
Inactivated Influenza Vaccine Prevents Respiratory Infections and Improves All-Cause and Cause-Specific Mortality in Immunosuppressed People with Autoimmune Rheumatic Diseases: Propensity Score Adjusted Cohort Study Using Data from Clinical Practice Research Datalink
Background/Purpose: To assess the effectiveness of inactivated influenza vaccine (IIV) in preventing influenza like illness (ILI), lower respiratory tract infection (LRTI), pneumonia, chronic obstructive pulmonary…Abstract Number: 1697 • 2018 ACR/ARHP Annual Meeting
Refractory Lupus Patients: How Frequent Do We See Them in the 21st Century?
Background/Purpose: management of systemic lupus erythematosus (SLE) patients is challenging because of the heterogeneity of the disease. While treatment of renal nephritis is more standardized,…Abstract Number: 2523 • 2018 ACR/ARHP Annual Meeting
Rapid Response with Upadacitinib Treatment in Patients with Rheumatoid Arthritis and an Inadequate Response to Csdmards or Bdmards
Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor selective for JAK1, demonstrated efficacy in patients (pts) with moderate to severe rheumatoid arthritis (RA) with an inadequate…Abstract Number: 544 • 2018 ACR/ARHP Annual Meeting
Does Anti-Citrullinated Protein Antibody Status Modify Treatment Effect of Certain Biologic DMARDs?
Background/Purpose: Multiple therapeutic options with different mechanistic actions are available to treat patients (pts) with RA. However, selecting therapies by the characteristics of pts with…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 24
- Next Page »